Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
3(100.0%)
3Total
Phase 1(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06936527Phase 1Enrolling By Invitation

XS-03 in Combination With FOLFOX or FOLFIRI and Bevacizumab for Treatment of Metastatic Colorectal Cancer Patients With RAS Mutation

Role: lead

NCT06820268Phase 1Recruiting

A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies

Role: lead

NCT06531486Phase 1Not Yet Recruiting

A Study of XS-02 Capsules in Patients With Advanced Solid Tumors

Role: lead

All 3 trials loaded